Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics, Inc. develops oral small-molecule therapies for neuroscience, inflammation and immunology indications. Company news centers on its clinical pipeline, including PIPE-791, an LPA1 receptor antagonist in development for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis and major depressive disorder.
Recurring updates include clinical trial data, PIPE-791 program progress, financial results, capital allocation commentary, investor conference participation and equity compensation actions under Nasdaq inducement-grant rules. Coverage also reflects the company’s Class A common stock structure and its status as a clinical-stage biopharmaceutical issuer.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharma focused on NI&I indications, granted an inducement stock option on May 14, 2026 to a new non-executive employee under its 2026 Employment Inducement Equity Incentive Plan.
The option covers 51,000 Class A shares, has a ten-year term, an exercise price equal to the Grant Date closing price, and vests over four years, with 25% after one year and the remainder monthly over 36 months.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharma focused on neuroscience, inflammation and immunology, will present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 3:35 p.m. ET. An audio webcast and replay will be available via the company’s investor relations website.
Contineum Therapeutics (NASDAQ: CTNM) will present two scientific posters on its lead investigational drug candidate PIPE-791 at the American Thoracic Society (ATS) 2026 International Conference in Orlando from May 15-20, 2026.
Both posters, focused on LPA1 antagonism and lung-related effects, are scheduled for May 18, 2026, and will also be available on Contineum’s website Publications page.
Contineum Therapeutics (NASDAQ: CTNM) reported Q1 2026 results and affirmed clinical milestones. Cash, cash equivalents and marketable securities were $246.3 million as of March 31, 2026, supporting a projected cash runway through mid-2029. Net loss was $14.5 million.
Clinical highlights: positive topline Phase 1b PIPE-791 chronic pain data (April 30, 2026); PROPEL-IPF Phase 2 dosing initiated in Q1 2026 (26-week, ~324 patients; primary endpoint: change in absolute FVC mL); J&J’s Phase 2 PIPE-307 Moonlight-1 trial is recruiting with estimated completion in June 2026.
Contineum Therapeutics (NASDAQ: CTNM) announced inducement equity awards to two new non-executive employees under its 2026 Employment Inducement Equity Incentive Plan. Each employee received a non-qualified option for 51,000 Class A shares, granted on April 28 and April 30, 2026.
Each option vests over four years (25% after one year, then monthly over 36 months), has a ten-year term, and an exercise price equal to the closing price on the applicable grant date. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Contineum Therapeutics (NASDAQ: CTNM) reported positive topline data from an exploratory Phase 1b PIPE-791 trial in chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). The randomized, double-blind, placebo-controlled, 4-week crossover study (N=43) tested oral 10 mg once-daily dosing.
The trial met its primary endpoint for safety and tolerability, showed no serious adverse events, and produced consistent numerical improvements versus placebo on PI-NRS pain measures and responder rates, supporting further clinical evaluation of PIPE-791.
Contineum Therapeutics (NASDAQ: CTNM) announced an inducement grant on March 12, 2026: a non-qualified stock option to purchase 51,000 shares of Class A common stock to a new non-executive employee under the Company’s 2026 Employment Inducement Equity Incentive Plan.
The option uses the closing price on the grant date as its exercise price, vests over four years (25% at one year, then monthly over 36 months), and has a ten-year term, subject to plan and option agreement terms and continued service.
Contineum Therapeutics (NASDAQ: CTNM) reported fourth-quarter 2025 results and affirmed clinical milestones. Key updates: patient dosing started in PROPEL-IPF, a global Phase 2 trial of PIPE-791; topline Phase 1b PIPE-791 data expected Q2 2026; cash, cash equivalents and marketable securities of $262.9M as of Dec 31, 2025, and a projected cash runway into mid-2029. The company completed an upsized public offering, generating $93.0M net proceeds. R&D was $12.8M and net loss was $15.2M in Q4 2025.
Contineum Therapeutics (NASDAQ: CTNM) will present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 at 2:20 p.m. ET. The management fireside chat will be available via an audio webcast on the company’s Investors website, with a replay posted afterwards.
Contineum Therapeutics (NASDAQ: CTNM) announced an inducement award for a new non-executive employee on February 17, 2026. The Compensation Committee granted a non-qualified stock option to purchase 51,000 Class A shares under the company’s 2026 Employment Inducement Equity Incentive Plan.
The option’s exercise price equals the closing price on the Grant Date, vests over 4 years (25% at one year, then monthly over 36 months), and has a 10-year term, subject to the plan and an option agreement.